Public Profile

Performance Updates

Want to track the performance of this manager?

Click the button below to sign up to receive monthly performance updates by email.

Track Manager
Invest Today

Want more information on investing with this manager?

If you are interested in investing in one of Justin Uyehara's funds. Click the link below to get started.

Invest Today

Justin Uyehara

  • Jan 28, 2003
Investment Strategy

Born in Okinawa, Japan, Justin Uyehara holds a degree in civil engineering from California State University, Sacramento. Gainfully employed in the structural engineering field, his true passion is investing. Justin is a self-described news junkie whose investment style is heavily influenced by the writings of market professionals such as Gary B. Smith and Bill Fleckenstein. He is the quintessential swing trader who finds opportunities to profit from big price swings in volatile markets.


Funds
(HMF) JU fund
MODEL INCEPTION (01/28/2003) AVG. ANNUAL RETURN S&P TOTAL RETURN Actions
14+ YRS 21.66% 10.01% View Fund Stats Track Fund
RETURN PERIOD (As Of: 09/30/2017) AVG. ANNUAL RETURN S&P TOTAL RETURN ACHIEVEMENTS
10 YRS 14.11% 7.24% Beat the top performing mutual fund over 10 years.  
5 YRS 1.29% 16.37% Fund has a 5 year track record.  
3 YRS -1.94% 11.16% Fund has a 3 year track record.  
1 YR -1.20% 15.43% Fund has a 1 year track record.  
Click Here to View More Information About This Fund.
Achievements
  • HMF Beat the top performing mutual fund over 10 years.
    Sep 30, 2017
Articles

    Cause For Celebration In The Duchenne Muscular Dystrophy Community

    The Duchenne Muscular Dystrophy (DMD) community today has reason to celebrate because the FDA finally granted approval for Sarepta’s (SRPT) eteplirsen. However, it is shameful that the FDA’s Read More...

    Novavax Gives Wall Street Underwriters A Sweet Deal

    Novavax (NASDAQ:NVAX) closed at $9.26 on Tuesday. On Wednesday, the stock closed at $7.98, down nearly 14%. On Thursday, it closed at $7.58 down another 5%. Here's what happened. Read More...

    Time To Sell Solazyme

    At the end of August, I wrote about Solazyme (NASDAQ:SZYM) as a company with the potential to double in two years. Since then, the stock has dropped 68%. In this article, I'll explain what happened, Read More...

    Can American Airlines Double?

    American Airlines is flush with plans and accomplishments including a recently completed merger with US Airways, a brand new operations center to be built in the Dallas/Fort Worth area by 2015, and Read More...

    Finding The Next Warren Buffett: Justin Uyehara

    Justin Uyehara has a 10 year track record with Marketocracy showing an annualized return of 30% a year. By comparison, the S&P 500 returned less than 9% a year during the same period. Justin is up a Read More...

Access Denied

You do not have permission to view this fund. Please select the "Overview" tab, or select a fund tab above.